PRAX as reported
Praxis Precision Medicines, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$339M
Net Income · +35% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$305M
Free Cash Flow · +60% year on year · trailing twelve months to Q2 2026
- EPS
- −$12.94
EPS · +4.8% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2025 |
| Net Income | −$339M | +35% | Q2 2026 |
| EPS | −$12.94 | +4.8% | Q2 2026 |
| Op Margin | −9974% | n/a | Q4 2024 · 6 quarters behind |
| Net Margin | −9076% | n/a | Q4 2024 · 6 quarters behind |
| ROE | −41% | n/a | Q2 2026 |
| ROA | −37% | n/a | Q2 2026 |
| Free Cash Flow | −$305M | +60% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Praxis Precision Medicines, Inc. (PRAX) - Revenue & ProfitRevenue & ProfitPraxis Precision Medicines, Inc. (PRAX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com